« Previous Next » Epilepsy Research
Volume 32, Issue 3 , Pages 371-378 , November 1998

Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine

M Bialer
- Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, PO Box 12065, Jerusalem 91120, Israel
- David R. Bloom Centre for Pharmacy, School of Pharmacy, Faculty of Medicine, The Hebrew University of JerusalemPO Box 12065, Jerusalem 91120, Israel
- Corresponding author. Tel.: +972 2 6758610; fax: +972 2 6436246; e-mail: bialer@md2.huji.ac.il
L Arcavi
- Clinical Pharmacology Unit, Department of Internal Medicine, Kaplan Hospital, Rehovot, Israel
S Sussan
- Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, PO Box 12065, Jerusalem 91120, Israel
A Volosov
- Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, PO Box 12065, Jerusalem 91120, Israel
A Yacobi
- Taro Pharmaceuticals, New York, USA
D Moros
- Taro Pharmaceuticals, New York, USA
- Department of Neurology, Mount Sinai Medical School, New York, USA
B Levitt
- Taro Pharmaceuticals, New York, USA
- Department of Medicine, Albert Einstein Medical School, New York, USA
A Laor
- Department of Internal Medicine, Lady Davis Carmel Hospital, Haifa, Israel